Intellia Therapeutics Stock Market Value
| NTLA Stock | USD 15.62 0.41 2.70% |
| Symbol | Intellia |
Intellia Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Intellia Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Intellia Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Intellia Therapeutics.
| 10/31/2024 |
| 11/30/2024 |
If you would invest 0.00 in Intellia Therapeutics on October 31, 2024 and sell it all today you would earn a total of 0.00 from holding Intellia Therapeutics or generate 0.0% return on investment in Intellia Therapeutics over 30 days. Intellia Therapeutics is related to or competes with Editas Medicine, Caribou Biosciences, Crispr Therapeutics, Verve Therapeutics, Beam Therapeutics, Fate Therapeutics, and Vertex Pharmaceuticals. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics More
Intellia Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Intellia Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Intellia Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 27.28 | |||
| Value At Risk | (7.15) | |||
| Potential Upside | 5.01 |
Intellia Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intellia Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Intellia Therapeutics' standard deviation. In reality, there are many statistical measures that can use Intellia Therapeutics historical prices to predict the future Intellia Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.16) |
Intellia Therapeutics Backtested Returns
Intellia Therapeutics holds Efficiency (Sharpe) Ratio of -0.0932, which attests that the entity had a -0.0932% return per unit of risk over the last 3 months. Intellia Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Intellia Therapeutics' Market Risk Adjusted Performance of (0.15), standard deviation of 4.37, and Risk Adjusted Performance of (0.07) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.85, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intellia Therapeutics will likely underperform. At this point, Intellia Therapeutics has a negative expected return of -0.41%. Please make sure to check out Intellia Therapeutics' daily balance of power, and the relationship between the skewness and day typical price , to decide if Intellia Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.53 |
Modest predictability
Intellia Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Intellia Therapeutics time series from 31st of October 2024 to 15th of November 2024 and 15th of November 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Intellia Therapeutics price movement. The serial correlation of 0.53 indicates that about 53.0% of current Intellia Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.53 | |
| Spearman Rank Test | 0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.47 |
Intellia Therapeutics lagged returns against current returns
Autocorrelation, which is Intellia Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Intellia Therapeutics' stock expected returns. We can calculate the autocorrelation of Intellia Therapeutics returns to help us make a trade decision. For example, suppose you find that Intellia Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Intellia Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Intellia Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Intellia Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Intellia Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Intellia Therapeutics Lagged Returns
When evaluating Intellia Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Intellia Therapeutics stock have on its future price. Intellia Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Intellia Therapeutics autocorrelation shows the relationship between Intellia Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Intellia Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Intellia Therapeutics Correlation, Intellia Therapeutics Volatility and Intellia Therapeutics Alpha and Beta module to complement your research on Intellia Therapeutics. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Intellia Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.